Phase III evaluation of the safety and efficacy of Clonicel (clonidine HCl sustained release) as add-on to psychostimulant medication vs. psychostimulant medication alone in children and adolescents with ADHD

Trial Profile

Phase III evaluation of the safety and efficacy of Clonicel (clonidine HCl sustained release) as add-on to psychostimulant medication vs. psychostimulant medication alone in children and adolescents with ADHD

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2011

At a glance

  • Drugs Clonidine (Primary) ; Central nervous system stimulants
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Addrenex Pharmaceuticals
  • Most Recent Events

    • 09 May 2011 Results published in the Pediatrics.
    • 09 May 2011 Results have been published in Pediatrics according to a Shionogi media release.
    • 04 Oct 2010 The US FDA has approved clonidine extended-release tablets based on results from this and another (32491) trial, according to a Shinogi Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top